% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • liv4ucf liv4ucf Sep 25, 2013 3:41 PM Flag

    Leerink swan Outperform Insmed - Target $ 22

    In the report, Leerink Swann noted, “With potentially pivotal but simultaneously proof-of-concept Arikace non-tuberculous mycobacteria (NTM) data imminent in 1Q:14, we have performed additional MEDACorp KOL checks and a more rigorous assessment of the TARGET protocol and have come away more bullish on Arikace's ability to generate an approvable portfolio of clinical data. We believe that some on the Street have been wary investing ahead of TARGET since its primary efficacy measure has never been utilized to support a drug approval. However, our additional due diligence has rendered us more confident as specialists highlight the diagnostic importance of sputum culture analyses, the clinical relevance of TARGET's secondary endpoints, and the seriousness of the NTM cases afflicting TARGET's patient population which could lower the bar for trial success. Reiterate OP rating on INSM and $22 PT in 12 months.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.5778-0.4522(-3.01%)10:31 AMEDT